Frontier IP Group - InSignals Neurotech Grant
REACH - non-regulatory announcement
AIM: FIPP
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio news - InSignals Neurotech secures grant funding to expand remote monitoring and launch Parkinson's app
Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company inSignals Neurotech ("inSignals" or "the Company") has been awarded a
InSignals is also launching a mobile app to support Parkinson's sufferers and caregivers to manage the disease more effectively. This work is being funded by a previous grant from PRR Green Vouchers. Frontier IP holds a 32.9 per cent equity stake in the Company.
The PT2030 framework is a European Union-backed structural programme to support
The funding will support a key strategic step for inSignals. It will use the grant to extend its proprietary algorithms to operate remotely through third-party wearable devices, including smartwatches and smart rings.
This development builds on the Company's clinically-validated technology and will enable continuous, real-world monitoring of Parkinson's disease outside clinical settings. By integrating with widely used consumer devices, inSignals aims to accelerate adoption, improve accessibility, and unlock scalable, data-driven care.
The approach also enables more responsive treatment optimisation, including integration with advanced therapies such as deep brain stimulation (DBS) and, potentially, infusion-based pharmacological treatments.
InSignals is currently undertaking a seed fundraising round to support the medical regulatory compliance and international expansion. The Company is engaging with investors who may benefit from
In parallel, inSignals is launching a mobile application designed specifically for people living with Parkinson's patients and their caregivers. The mobile app will enable ongoing symptom monitoring and improve communication with clinicians. This marks an important step in expanding the Company's offering beyond clinical tools into patient-facing digital health solutions.
InSignals' technology has been extensively validated and tested in more than 200 patients across an international multi-centre clinical study. As a pioneer in objective rigidity measurement, inSignals holds patents covering rigidity quantification methods.
The Company is a spin out from the Portuguese Institute for Systems and Computer Engineering, Technology and Science ("INESC TEC") with the support of São João University Hospital, part of the University of Porto. It was established to commercialise the research of Professor
InSignals has been recognised as one of
InSignals Neurotech Co-founder and CSO
Frontier IP Chief Executive Officer
ENQUIRIES
|
Frontier IP Group Plc |
|
|
Company website: www.frontierip.co.uk |
andrew.johnson@frontierip.co.uk M: 07415 888 425 |
|
inSignals Neurotech |
|
|
Allenby Capital Limited (Nominated Adviser and Joint Broker)
|
|
|
Shore Capital (Joint Broker) James Thomas /
|
T: 0207 408 4050 |
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulations would be disseminated as an RNS regulatory announcement and not on Reach.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE